{"id":"https://openalex.org/W1994462732","doi":"https://doi.org/10.1002/mpo.2950040104","title":"Phase II study of subcutaneously administered 5\u2010azacytidine (NSC\u2010102816) in patients with metastatic malignant melanoma","display_name":"Phase II study of subcutaneously administered 5\u2010azacytidine (NSC\u2010102816) in patients with metastatic malignant melanoma","publication_year":1978,"publication_date":"1978-01-01","ids":{"openalex":"https://openalex.org/W1994462732","doi":"https://doi.org/10.1002/mpo.2950040104","mag":"1994462732","pmid":"https://pubmed.ncbi.nlm.nih.gov/75498"},"language":"en","primary_location":{"id":"doi:10.1002/mpo.2950040104","doi":"https://doi.org/10.1002/mpo.2950040104","is_oa":false,"landing_page_url":"https://doi.org/10.1002/mpo.2950040104","pdf_url":null,"source":{"id":"https://openalex.org/S179546387","display_name":"Medical and Pediatric Oncology","issn_l":"0098-1532","issn":["0098-1532","1096-911X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4310320571","host_organization_name":"Alan R. Liss, Inc.","host_organization_lineage":["https://openalex.org/P4310320571"],"host_organization_lineage_names":["Alan R. Liss, Inc."],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Medical and Pediatric Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5109380757","display_name":"Robert E. Bellet","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1289437631","display_name":"Fox Chase Cancer Center","ror":"https://ror.org/0567t7073","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1289437631","https://openalex.org/I4210122924"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Robert E. Bellet","raw_affiliation_strings":["Fox Chase Cancer Center, Philadelphia, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fox Chase Cancer Center, Philadelphia, Pennsylvania","institution_ids":["https://openalex.org/I1289437631"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112262359","display_name":"Robert B. Catalano","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1289437631","display_name":"Fox Chase Cancer Center","ror":"https://ror.org/0567t7073","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1289437631","https://openalex.org/I4210122924"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. B. Catalano","raw_affiliation_strings":["Fox Chase Cancer Center Philadelphia Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fox Chase Cancer Center Philadelphia Pennsylvania","institution_ids":["https://openalex.org/I1289437631"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110153353","display_name":"Michael J. Mastrangelo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1289437631","display_name":"Fox Chase Cancer Center","ror":"https://ror.org/0567t7073","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1289437631","https://openalex.org/I4210122924"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael J. Mastrangelo","raw_affiliation_strings":["Fox Chase Cancer Center, Philadelphia, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fox Chase Cancer Center, Philadelphia, Pennsylvania","institution_ids":["https://openalex.org/I1289437631"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5045802455","display_name":"David Berd","orcid":"https://orcid.org/0000-0003-2974-9085","observed_orcids":["https://orcid.org/0000-0003-2974-9085"]},"institutions":[{"id":"https://openalex.org/I1289437631","display_name":"Fox Chase Cancer Center","ror":"https://ror.org/0567t7073","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1289437631","https://openalex.org/I4210122924"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Berd","raw_affiliation_strings":["Fox Chase Cancer Center, Philadelphia, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fox Chase Cancer Center, Philadelphia, Pennsylvania","institution_ids":["https://openalex.org/I1289437631"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5109380757"],"corresponding_institution_ids":["https://openalex.org/I1289437631"],"apc_list":null,"apc_paid":null,"fwci":0.7954,"has_fulltext":false,"cited_by_count":11,"citation_normalized_percentile":{"value":0.73102094,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":94},"biblio":{"volume":"4","issue":"1","first_page":"11","last_page":"15"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.9429000020027161,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.9429000020027161,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.016100000590085983,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.008299999870359898,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/azacitidine","display_name":"azacitidine","score":0.9990000128746033},{"id":"https://openalex.org/keywords/metastatic-melanoma","display_name":"metastatic melanoma","score":0.9229999780654907},{"id":"https://openalex.org/keywords/subcutaneous-administration","display_name":"subcutaneous administration","score":0.9259999990463257},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.7429999709129333},{"id":"https://openalex.org/keywords/drug-toxicity","display_name":"drug toxicity","score":0.7239999771118164},{"id":"https://openalex.org/keywords/hematological-toxicity","display_name":"hematologic toxicity","score":0.9210000038146973},{"id":"https://openalex.org/keywords/gastrointestinal-toxicity","display_name":"gastrointestinal toxicity","score":0.9269999861717224},{"id":"https://openalex.org/keywords/skin-toxicity","display_name":"skin toxicity","score":0.9890000224113464}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9390479922294617},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.6931337118148804},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.6439597010612488},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.6373037099838257},{"id":"https://openalex.org/C2776946711","wikidata":"https://www.wikidata.org/wiki/Q418311","display_name":"Nitrosourea","level":3,"score":0.5440828204154968},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.4972827732563019},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4288782477378845},{"id":"https://openalex.org/C2994587330","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Metastatic melanoma","level":3,"score":0.42402440309524536},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4190727472305298},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.408800333738327},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3524302840232849},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3499576449394226},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.17156293988227844},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D001374","descriptor_name":"Azacitidine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D001374","descriptor_name":"Azacitidine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D001374","descriptor_name":"Azacitidine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001853","descriptor_name":"Bone Marrow","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D003606","descriptor_name":"Dacarbazine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D004341","descriptor_name":"Drug Evaluation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004351","descriptor_name":"Drug Resistance","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007279","descriptor_name":"Injections, Subcutaneous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009362","descriptor_name":"Neoplasm Metastasis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D014839","descriptor_name":"Vomiting","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1002/mpo.2950040104","doi":"https://doi.org/10.1002/mpo.2950040104","is_oa":false,"landing_page_url":"https://doi.org/10.1002/mpo.2950040104","pdf_url":null,"source":{"id":"https://openalex.org/S179546387","display_name":"Medical and Pediatric Oncology","issn_l":"0098-1532","issn":["0098-1532","1096-911X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4310320571","host_organization_name":"Alan R. Liss, Inc.","host_organization_lineage":["https://openalex.org/P4310320571"],"host_organization_lineage_names":["Alan R. Liss, Inc."],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Medical and Pediatric Oncology","raw_type":"journal-article"},{"id":"pmid:75498","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/75498","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Medical and pediatric oncology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9822999835014343,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320332505","display_name":"U.S. Public Health Service","ror":"https://ror.org/05xf94514"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":11,"referenced_works":["https://openalex.org/W46607909","https://openalex.org/W145038933","https://openalex.org/W1517594014","https://openalex.org/W2065274864","https://openalex.org/W2073717790","https://openalex.org/W2091201175","https://openalex.org/W2094037657","https://openalex.org/W2147699230","https://openalex.org/W2395930030","https://openalex.org/W2405434337","https://openalex.org/W6605859678"],"related_works":["https://openalex.org/W2405434337","https://openalex.org/W145038933","https://openalex.org/W46662938","https://openalex.org/W2412462299","https://openalex.org/W174558166","https://openalex.org/W2464555249","https://openalex.org/W2410316872","https://openalex.org/W2415174732","https://openalex.org/W2398830679","https://openalex.org/W2413786695"],"abstract_inverted_index":{"Thirty":[0],"(30)":[1],"patients":[2,35],"with":[3,17],"advanced":[4],"metastatic":[5],"malignant":[6],"melanoma":[7],"refractory":[8],"to":[9],"DTIC":[10],"(NSC-45388)":[11],"and":[12,40,48],"a":[13,25],"nitrosourea":[14],"were":[15,36,45],"treated":[16],"5-azacytidine":[18],"(NSC-102816).":[19],"5-Azacytidine":[20],"was":[21,53],"administered":[22],"subcutaneously":[23],"at":[24],"dosage":[26],"of":[27],"100":[28],"mg/m2/day":[29],"for":[30,38],"10":[31],"days.":[32],"Twenty-six":[33],"(26)":[34],"evaluable":[37],"toxicity":[39],"response.":[41],"Major":[42],"organ":[43],"toxicities":[44],"hematologic,":[46],"gastrointestinal,":[47],"cutaneous;":[49],"no":[50],"antitumor":[51],"activity":[52],"noted.":[54]},"counts_by_year":[{"year":2020,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2015,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}